Overview

Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects

Status:
Not yet recruiting
Trial end date:
2022-04-16
Target enrollment:
Participant gender:
Summary
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy chinese adult
Phase:
Phase 1
Details
Lead Sponsor:
Anhui Palo Alto Pharmaceuticals, Inc.
Treatments:
Pharmaceutical Solutions